Vanda Pharmaceuticals Inc.

Michel Burcklen

Andrea Vaclavkova

Brian Patrick Hennessy

Tatiana Sidorenko

Hilke Kracker

Sivi Ouwerkerk-Mahadevan

Allitia DiBernardo

Alexander Keenan

Tarek El Akkad

The disclosure relates to methods of treating multiple sclerosis using Ponesimod. In certain aspects, these include methods of avoiding worsening of fatigue-related symptoms in a human patient who has had no prior disease modifying treatment (DMT) for multiple sclerosis, who has a baseline expanded disability status scale (EDSS) score of ≤3.5, or who does not have Gd+/T1 lesions at baseline.

Ponesimod for avoiding worsening of fatigue-related symptoms in multiple sclerosis patients

The disclosure relates to methods of treating multiple sclerosis. Also provided are pharmaceutical products containing ponesimod, instructions for use of ponesimod, methods for selling a drug product containing ponesimod, and methods for reducing clinical management events before or during treatment of multiple sclerosis.

Methods of treating multiple sclerosis

Growing community of inventors

Allschwil, Switzerland

Michel Burcklen